For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: Sitagliptin Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3. Other Name: Januvia